Navigation Links
MAP Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
Date:1/4/2011

MOUNTAIN VIEW, Calif., Jan. 4, 2011 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the company will present at the 29th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2011 at 8:00 a.m. PT in San Francisco.

A live webcast of the presentation will be available on the Investor Relations section of MAP Pharmaceuticals' website at http://www.mappharma.com. A replay will also be available within 24 hours for seven days following the presentation.

About MAP Pharmaceuticals MAP Pharmaceuticals is an emerging biopharmaceutical company focused on developing and commercializing new therapies to address undermet patient needs in neurology. The Company is developing LEVADEX™ orally inhaled therapy for the potential treatment of migraine and has reported positive results from the efficacy portion of its Phase 3 trial of LEVADEX. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history.

Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com. CONTACT: Alex BowieWCG(212) 301-7201abowie@wcgworld.com
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... 17, 2017   Parker Waichman LLP, ... rights of victims injured by medical devices, comments ... call for better reporting. Congress required hospitals to ... concerns involving power morcellators and duodenoscopes prompted the ... how hospitals report injuries and deaths related to ...
(Date:2/17/2017)... CINCINNATI , Feb. 17, 2017  Ethicon, ... Torax Medical, Inc., a privately held medical device ... Reflux Management System, a novel minimally invasive ... acquisition of Torax Medical will enable Ethicon to ... the anatomy-altering laparoscopic Nissen fundoplication surgical procedure. 1 ...
(Date:2/17/2017)... (NYSE, TASE: PRGO) today announced it has received final approval ... and homatropine methylbromide oral solution (syrup), 5 mg/1.5 mg per ... oral solution (syrup), 5 mg/1.5 mg per 5 mL is ... children 6 years of age and older. Annual sales for ...   ...
Breaking Medicine Technology:
(Date:2/18/2017)... ... ... Butler Mobility invited Ken Matthews to visit its manufacturing facility and showroom ... impressed with the safety and reliability of the Stannah Stairlift as well as with ... endorsement by Ken Matthews can be heard on News Radio WHP 580 weekdays from ...
(Date:2/17/2017)... , ... February 17, 2017 , ... Smiles by Seese ... Center in Davidson, NC. Dr. Brian Seese leads the practice as a skilled and ... under one roof. Smiles by Seese serves patients of all ages with excellence in ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... Feb. 22, 2017 — 1:30 p.m. – 2:30 p.m. ET, http://www.fdanews.com/deviceapproval ... asking before selecting an FDA approval pathway? , How should they evaluate ...
(Date:2/17/2017)... ... February 17, 2017 , ... Program will ... Trinity Health and the U.S. Soccer Foundation announced today that they have awarded ... Soccer for Success, the Foundation’s soccer mentoring program, teaches kids the fundamentals of ...
(Date:2/17/2017)... ... ... Like most hospitals across the nation, Onslow Memorial Hospital is looking for ... Reduction Program (HRRP), the return of a patient to the hospital within 30 days ... many providers are struggling to leverage limited resources and technology, Onslow Memorial Hospital has ...
Breaking Medicine News(10 mins):